Results from randomized controlled trials indicate that about one-third of RA patients initially treated with anti-tumor necrosis factor α (anti-TNF) agents do not respond, show a suboptimal response, lose response, or develop adverse events [1]. This evidence concerns the gene TNF and rheumatoid arthritis.